CORIN and neoplasm: Interestingly, Hugo et al. (28) previously noted genes with loss-of-function gene-based events (including transcriptional downregulation) in tumors from patients following acquired MAPKi resistance, and this gene signature was positively enriched with corin plus PLX4032 treatment of 451Lu-R and 1205Lu-R cells compared with PLX4032 alone, with several of the corin-upregulated genes confirmed by RT-qPCR, suggesting a specific effect on tumor-associated MAPKi resistance pathways (Supplemental Figure 6, A–C and Supplemental Table 8).